sorbinil
Sorbinil (INN) is an aldose reductase inhibitor being investigated for treatment of diabetic complications including neuropathy and retinopathy. Aldose reductase is an enzyme present in lens and brain that removes excess glucose by converting it to sorbitol. Sorbitol accumulation can lead to the development of cataracts in the lens and neuropathy in peripheral nerves. Sorbinil has been shown to inhibit aldose reductase in human brain and placenta and calf and rat lens. Sorbinil reduced sorbitol accumulation in rat lens and sciatic nerve of diabetic rats orally administered 0.25 mg/kg sorbinil. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 1983 (NCT00000159)
Timeline
1980s
- Jan 1, 1983
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Aldose reductaseINHIBITOR
Aldose reductase inhibitor
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
O=C1NC(=O)[C@@]2(CCOc3ccc(F)cc32)N1- Mol. weight
- 236.2 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSorbinil ↗
- ChEMBLCHEMBL266497 ↗
Also known as
- cp 45634
- cp-45634
- cp-45634
- cp-45634
- d-6-fluoro-spiro(chroman-4,4'-imidazolidine)-2',5'-dione
- sbi
- sorbinil
- sorbinil
- sorbinil
- sorbinil
- sorbinil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000159 | Phase 3 | Aug 1, 1983 | National Eye Institute (NEI) |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Eye Institute (NEI) | Government | 1 | 1 | 1 | 1983 |